翰森製藥(03692.HK):B7-H3靶向抗體–藥物偶聯物HS-20093用於骨肉瘤獲國家藥品監督管理局納入突破性治療藥物
格隆匯2月25日丨翰森製藥(03692.HK)發佈公吿,於2025年2月25日,集團自研B7-H3靶向抗體–藥物偶聯物(ADC)注射用HS-20093獲中國國家藥品監督管理局(NMPA)批准納入突破性治療藥物,擬定適應症為用於治療經至少二線治療後進展的骨肉瘤患者。
HS-20093是一種B7-H3靶向ADC,由全人源抗B7-H3單抗與拓撲異構酶抑制劑(TOPOi)有效載荷共價連接而成,正於中國開展用於治療肺癌、肉瘤、頭頸癌以及其他實體瘤的多項臨牀研究,其中最高研究階段為臨牀III期。於2024年11月1日,HS-20093用於經標準一線治療(含鉑雙藥化療聯合免疫)後進展的廣泛期小細胞肺癌(ES-SCLC)適應症已被NMPA納入突破性治療藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.